comparemela.com

Latest Breaking News On - Thomask equels - Page 10 : comparemela.com

AIM ImmunoTech Inc.: AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast

AIM ImmunoTech Inc.: AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Thomask-equels
Christopher-mcaleer
Facebook
Company-on-twitter
Linkedin
Immunotech-inc
Chief-executive-officer
Ihre-watchlist

AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast

09.11.2023 - OCALA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) - AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the Company’s Q3 2023 operational and financial .

United-states
American
Thomask-equels
Christopher-mcaleer
Immunotech-inc
Tech-inc
Chief-executive-officer
Tech-conference
Aim-immunotech-chart
Im-immunotech-kurs
Im-immunotech-aktie

AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer

AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San-diego
California
United-states
American
Robert-edwards
David-strayer
Thomask-equels
Robertp-edwards
Magee-womens-research-institute
Twitter
Services-division
University-of-pittsburgh-school-medicine

AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders

Highlights AIM’s Significant Momentum and Ongoing Achievement of Clinical and Regulatory Milestones Urges Shareholders to Protect AIM’s Progress by Voting for the Company’s Board of Directors.

Delaware
United-states
Netherlands
Nebraska
American
Thomask-equels
Michaelj-xirinachs
Franzn-tudor
Astrazeneca-imfinzi
Williamm-mitchell
Robertl-chioini
Nancyk-bryan

AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs

AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
American
Stacy-evans
Jeff-southerton
Thomask-equels
Linkedin
Facebook
Twitter
Immunotech-inc
Executive-officer-thomas
Private-securities-litigation-reform-act
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.